A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
/PRNewswire/ OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Shield Therapeutics.
TRADING UPDATES: Pelatro gets contracts; Futura raises GBP10 million
Mon, 17th May 2021 15:04
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Pelatro PLC - London-based marketing software specialist - Secures several contracts for change requests, worth around USD300,000, that will be delivered in 2021. With these, the total value of contracts in hand representing 2021 revenue is around USD6.8 million. Comes around a month after firm reports getting several contracts for change requests, adding up to USD500,000, that brought total value of work in hand for 2021 revenue to USD6.5 million. Given that we have clear visibility with contracts secured for USD6.8 million of revenue for 2021 so early in the year, together with the momentum we are building in our business, we are looking forward to a successful outcome this year in line with expectations, says Chief Executive & Managing
Shield Therapeutics says OTCQX Best Market listing ahead of Accrufer US launch has great potential
Shield Therapeutics PLC s (LON:STX), Tim Watts talks to Proactive London about their new US stock market quote on the OTCQX Best Market.
This decision is to support the upcoming launch of Accrufer in the US with the aim to increase relevance to US-based investors.
Watts explains that they will face no additional reporting requirements as a result of the American listing, therefore the additional costs will be minimal .
Watts believes the drug has the potential to reach the realm of £100mln worth of sales in the first three years and then on to 3-400mln by years five or six .
A Uyghur activist in Australia who has been the target of cyber-attacks by hacker groups in China says the Australian government needs to do more to educate the Uyghur community in Australia to protect themselves online. Uyghur activists outside of China are frequently the target of hackers based in China. Facebook’s head of cyber-espionage investigations, Mike Dvilyanksi, and head of security policy, Nathaniel Gleicher, reported in March that a.